Nosebleed No More: Recognizing and Diagnosing Factor VIII Inhibitor
Speaker Credentials
MDIV
Speaker Credentials
MD
College
College of Allopathic Medicine
Format
Poster
Start Date
November 2024
End Date
November 2024
Track
3
Abstract
Acquired hemophilia is a condition characterized by the unexpected onset of severe bleeding due to an issue with coagulation factors. Typically, this disorder results from the production of autoantibodies against the Factor VIII coagulation factor. Although acquired hemophilia is an extremely rare condition, with an annual incidence of just 1.5 cases per million, it is crucial to recognize and understand it. This is because diagnosing this disorder is intricate, and if left undiagnosed and untreated, it can lead to high levels of morbidity and mortality. This case stands out as the condition typically targets older adults, with around 80% of patients being 65 years or older, with the median age ranging from 73.9 years to 78 years. In this particular case, the patient is a 56-year-old Hispanic female. This underscores the importance of considering this diagnosis in younger individuals as well, as it can impact those under the age of 65. Acquired hemophilia provides valuable lessons for healthcare providers and remains an intriguing subject for ongoing research, as there are still many aspects of this condition that continue to elude our full understanding. Notably, nearly half of the diagnosed cases of acquired hemophilia have no identifiable cause or precipitating factor. Meanwhile, the other half encompasses a wide range of etiologies, with the most common cause, accounting for approximately 17-18% of cases, being the association with immunologic disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and various other autoimmune diseases.
Nosebleed No More: Recognizing and Diagnosing Factor VIII Inhibitor
Acquired hemophilia is a condition characterized by the unexpected onset of severe bleeding due to an issue with coagulation factors. Typically, this disorder results from the production of autoantibodies against the Factor VIII coagulation factor. Although acquired hemophilia is an extremely rare condition, with an annual incidence of just 1.5 cases per million, it is crucial to recognize and understand it. This is because diagnosing this disorder is intricate, and if left undiagnosed and untreated, it can lead to high levels of morbidity and mortality. This case stands out as the condition typically targets older adults, with around 80% of patients being 65 years or older, with the median age ranging from 73.9 years to 78 years. In this particular case, the patient is a 56-year-old Hispanic female. This underscores the importance of considering this diagnosis in younger individuals as well, as it can impact those under the age of 65. Acquired hemophilia provides valuable lessons for healthcare providers and remains an intriguing subject for ongoing research, as there are still many aspects of this condition that continue to elude our full understanding. Notably, nearly half of the diagnosed cases of acquired hemophilia have no identifiable cause or precipitating factor. Meanwhile, the other half encompasses a wide range of etiologies, with the most common cause, accounting for approximately 17-18% of cases, being the association with immunologic disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and various other autoimmune diseases.